SCHEMBL25864245

SCHEMBL25864245

Nc1ncnc2c1ncn2[C@@H]1C[C@H](C[C@@H](N)CC[C@H](N)C(=O)O)[C@@H](O)[C@H]1O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HNMT P50135 1/20 0.75
NNMT P40261 3/20 0.67
PRMT5 O14744 3/20 0.67
NSD2 O96028 2/20 0.67
PCMT1 P22061 2/20 0.67
DOT1L Q8TEK3 2/20 0.67
SETD7 Q8WTS6 2/20 0.67
EHMT2 Q96KQ7 2/20 0.67
TRDMT1 O14717 1/20 0.67
RNMT O43148 1/20 0.67
INMT O95050 1/20 0.67
TPMT P51580 1/20 0.67
METTL3 Q86U44 1/20 0.67
CARM1 Q86X55 1/20 0.67
NSD1 Q96L73 1/20 0.67
PRMT1 Q99873 1/20 0.67
SETD2 Q9BYW2 1/20 0.67
NSD3 Q9BZ95 1/20 0.67
EHMT1 Q9H9B1 1/20 0.67
METTL14 Q9HCE5 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27092934 0.87 HNMT (0.73) HNMTNNMTPRMT5NSD2PCMT1
SCHEMBL27092929 0.87 HNMT (0.73) HNMTNNMTPRMT5NSD2PCMT1
SCHEMBL27092971 0.86 HNMT (1.00) HNMTNNMTPRMT5NSD2PCMT1
SCHEMBL27092976 0.86 HNMT (1.00) HNMTNNMTPRMT5NSD2PCMT1
SCHEMBL25864251 0.85 DOT1L (0.64) HNMTNNMTPRMT5NSD2PCMT1
Sinefungin SCHEMBL24478706 0.80 NSD2 (1.00) HNMTNNMTPRMT5NSD2PCMT1
Sinefungin SCHEMBL10400321 0.80 NSD2 (1.00) HNMTNNMTPRMT5NSD2PCMT1
Sinefungin SCHEMBL38665462 0.80 NSD2 (1.00) HNMTNNMTPRMT5NSD2PCMT1
Sinefungin SCHEMBL167609 0.80 NSD2 (1.00) HNMTNNMTPRMT5NSD2PCMT1
Sinefungin SCHEMBL20992057 0.80 NSD2 (1.00) HNMTNNMTPRMT5NSD2PCMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230233592-A1 PHARMACEUTICAL COMPOSITION FOR THE CHEMICAL INHIBITION OF TGS1 IN THE THERAPEUTIC TREATMENT OF TELOMEROPATHIES UNIVERSITÀ DEGLI STUDI DI ROMA "LA SAPIENZA" (IT) 2023-07-27 US disclosed
US-20230233592-A1 PHARMACEUTICAL COMPOSITION FOR THE CHEMICAL INHIBITION OF TGS1 IN THE THERAPEUTIC TREATMENT OF TELOMEROPATHIES UNIVERSITÀ DEGLI STUDI DI ROMA "LA SAPIENZA" (IT) 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230233592-A1 PHARMACEUTICAL COMPOSITION FOR THE CHEMICAL INHIBITION OF TGS1 IN THE THERAPEUTIC TREATMENT OF TELOMEROPATHIES POT1, SPTLC1, GAR1 HNMT 2716/4885NNMT 2881/4885PRMT5 347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.